What is Lixte Biotechnology Hldgs Inc's earnings per share (EPS)?

Lixte Biotechnology Hldgs Inc (LIXT) reported diluted earnings per share of $-1.26 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lixte Biotechnology Hldgs Inc Financials

LIXT

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Lixte Biotechnology Hldgs Inc (LIXT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.51x

For every $1 of reported earnings, Lixte Biotechnology Hldgs Inc generates $0.51 in operating cash flow (-$3.1M OCF vs -$6.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-557.7x

Lixte Biotechnology Hldgs Inc earns $-557.7 in operating income for every $1 of interest expense (-$5.1M vs $9K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$6.1M

YoY-69.5%

Lixte Biotechnology Hldgs Inc reported -$6.1M in net income in fiscal year 2025. This represents a decrease of 69.5% from the prior year.

EPS (Diluted)

$-1.26

Lixte Biotechnology Hldgs Inc earned $-1.26 per diluted share (EPS) in fiscal year 2025. This represents an increase of 20.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

12M

Lixte Biotechnology Hldgs Inc had 12M shares outstanding in fiscal year 2025. This represents an increase of 416.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$255K

YoY-64.9%

5Y CAGR-26.9%

10Y CAGR-19.0%

Lixte Biotechnology Hldgs Inc invested $255K in research and development in fiscal year 2025. This represents a decrease of 64.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

LIXT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$255K-64.9%	$726K-19.1%	$898K-33.4%	$1.3M-22.3%	$1.7M+41.9%	$1.2M
SG&A Expenses	$4.9M+70.5%	$2.8M-32.1%	$4.2M+64.6%	$2.5M-15.8%	$3.0M+295.3%	$765K
Operating Income	-$5.1M-43.0%	-$3.6M+29.8%	-$5.1M+19.3%	-$6.3M+6.1%	-$6.7M-105.7%	-$3.3M
Interest Expense	$9K-45.6%	$17K+3.6%	$16K+82.9%	$9K+19.7%	$7K+101.8%	$4K
Income Tax	$2K	N/A	N/A	N/A	N/A	N/A
Net Income	-$6.1M-69.5%	-$3.6M+29.5%	-$5.1M+19.4%	-$6.3M+6.2%	-$6.7M-106.1%	-$3.3M
EPS (Diluted)	$-1.26	$-1.59+40.2%	$-2.66+33.3%	$-3.99	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$51K-16.4%	$61K-33.7%	$91K	N/A	$362K+71.6%	$211K+77.0%	$119K	N/A
SG&A Expenses	$1.8M+145.1%	$714K+16.0%	$615K	N/A	$622K-22.1%	$798K-5.8%	$848K	N/A
Operating Income	-$1.8M-132.5%	-$775K-9.6%	-$707K	N/A	-$983K+2.6%	-$1.0M-4.4%	-$967K	N/A
Interest Expense	$457-74.8%	$2K-42.3%	$3K	N/A	$1K-74.7%	$4K-42.2%	$7K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.0M-155.3%	-$776K-9.3%	-$710K	N/A	-$986K+2.5%	-$1.0M-4.1%	-$971K	N/A
EPS (Diluted)	$-0.33-13.8%	$-0.290.0%	$-0.29	N/A	$-0.44+2.2%	$-0.45-4.7%	$-0.43	N/A

LIXT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$1.1M-73.4%	$4.3M-22.5%	$5.6M+9.2%	$5.1M-2.6%	$5.2M
Current Assets	N/A	$1.1M-73.4%	$4.3M-22.5%	$5.6M+9.2%	$5.1M-2.6%	$5.2M
Cash & Equivalents	N/A	$1.0M-75.3%	$4.2M-21.5%	$5.4M+11.0%	$4.8M-4.8%	$5.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$318K+1.4%	$314K-20.7%	$396K+30.6%	$303K+39.9%	$217K
Current Liabilities	N/A	$318K+1.4%	$314K-20.7%	$396K+30.6%	$303K+39.9%	$217K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$827K-79.3%	$4.0M-22.7%	$5.2M+7.8%	$4.8M-4.4%	$5.0M
Retained Earnings	N/A	-$52.1M-7.4%	-$48.5M-11.7%	-$43.4M-17.0%	-$37.1M-22.2%	-$30.4M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$5.4M+357.2%	$1.2M-21.5%	$1.5M+32.2%	$1.1M-32.5%	$1.7M-36.4%	$2.7M-25.7%	$3.6M-16.7%	$4.3M
Current Assets	$5.4M+449.0%	$990K	N/A	$1.1M-32.2%	$1.7M-36.7%	$2.7M-25.7%	$3.6M-16.7%	$4.3M
Cash & Equivalents	$2.9M+225.5%	$887K-35.9%	$1.4M+33.3%	$1.0M-36.6%	$1.6M-36.9%	$2.6M-24.0%	$3.4M-18.8%	$4.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$521K-2.9%	$537K+51.3%	$355K+11.6%	$318K-3.2%	$329K-21.9%	$421K-8.9%	$463K+47.5%	$314K
Current Liabilities	$521K-2.9%	$537K+51.3%	$355K+11.6%	$318K-3.2%	$329K-21.9%	$421K-8.9%	$463K+47.5%	$314K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.9M+654.0%	$651K-43.8%	$1.2M+40.1%	$827K-39.5%	$1.4M-39.1%	$2.2M-28.2%	$3.1M-21.7%	$4.0M
Retained Earnings	-$55.5M-3.7%	-$53.6M-1.5%	-$52.8M-1.4%	-$52.1M-1.2%	-$51.4M-2.0%	-$50.5M-2.0%	-$49.5M-2.0%	-$48.5M

LIXT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$3.1M+3.0%	-$3.2M+26.3%	-$4.3M+6.9%	-$4.6M-11.3%	-$4.1M-94.4%	-$2.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$3.2M	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$10.3M	N/A	$3.1M-38.9%	$5.1M+31.9%	$3.9M-15.3%	$4.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$927K-90.1%	-$487K+14.2%	-$568K+5.0%	-$599K+37.5%	-$958K-16.9%	-$819K-3.8%	-$789K+12.5%	-$902K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$5.6M+55747.7%	-$10K-101.1%	$914K	N/A	N/A	N/A	N/A	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

LIXT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-433.5%-306.2pp	-127.3%-5.1pp	-122.2%+18.3pp	-140.5%-75.3pp	-65.1%
Return on Assets	N/A	-313.1%-195.0pp	-118.1%-4.6pp	-113.5%+18.6pp	-132.1%-69.7pp	-62.4%
Current Ratio	N/A	3.60-10.1	13.73-0.3	14.05-2.8	16.81-7.3	24.15
Debt-to-Equity	N/A	0.38+0.3	0.080.0	0.08+0.0	0.06+0.0	0.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-40.3%+78.8pp	-119.1%-57.9pp	-61.2%	N/A	-72.1%-27.1pp	-45.0%-13.9pp	-31.1%	N/A
Return on Assets	-36.4%+28.8pp	-65.3%-18.4pp	-46.9%	N/A	-58.1%-20.2pp	-37.9%-10.8pp	-27.1%	N/A
Current Ratio	10.42+8.6	1.84	N/A	3.60-1.5	5.13-1.2	6.33-1.4	7.75-6.0	13.73
Debt-to-Equity	0.11-0.7	0.82+0.5	0.31-0.1	0.38+0.1	0.24+0.1	0.19+0.0	0.15+0.1	0.08
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Akari Therapeutics Plc AKTX

$5.3M

Q32 BIO INC QTTB

$89.4M

BOUNDLESS BIO INC BOLD

$25.3M

Propanc Bio PPCB

$1.8M

Allarity ALLR

$18.2M

Frequently Asked Questions

Is Lixte Biotechnology Hldgs Inc profitable?

No, Lixte Biotechnology Hldgs Inc (LIXT) reported a net income of -$6.1M in fiscal year 2025.

What is Lixte Biotechnology Hldgs Inc's operating cash flow?

Lixte Biotechnology Hldgs Inc (LIXT) generated -$3.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

How much does Lixte Biotechnology Hldgs Inc spend on research and development?

Lixte Biotechnology Hldgs Inc (LIXT) invested $255K in research and development during fiscal year 2025.

How many shares does Lixte Biotechnology Hldgs Inc have outstanding?

Lixte Biotechnology Hldgs Inc (LIXT) had 12M shares outstanding as of fiscal year 2025.

Are Lixte Biotechnology Hldgs Inc's earnings high quality?

Lixte Biotechnology Hldgs Inc (LIXT) has an earnings quality ratio of 0.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Lixte Biotechnology Hldgs Inc cover its interest payments?

Lixte Biotechnology Hldgs Inc (LIXT) has an interest coverage ratio of -557.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.